Craft
Ypsomed

Ypsomed

Revenue

CHF464.8 M

FY, 2022

Market Capitalization

CHF2 B

2022-09-20

Ypsomed Summary

Company summary

Overview
Ypsomed is a company that develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. It operates through Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others segments. The Ypsomed Delivery Systems segment offers various injection systems, such as pen injectors, auto injectors and dual-chamber pens, as well as insulin pens, other diabetes pens, pens for growth hormones and other pens. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories and other day-to-day items for diabetics. The Others segment offers precision turned parts.
Type
Public
Founded
2003
HQ
Burgdorf, CH | view all locations
Website
https://www.ypsomed.com/en/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Simon Michel

    Simon Michel, Chief Executive Officer

  • Niklaus Ramseier

    Niklaus Ramseier, Chief Financial Officer (CFO)

    • Frank Mengis

      Frank Mengis, Chief Operating Officer (COO)

      LocationsView all

      22 locations detected

      • Burgdorf, BE HQ

        Switzerland

        Brunnmattstrasse 6

      • Mona Vale, NSW

        Australia

        602/20 Bungan St

      • Wien, Wien

        Austria

        Am Europl. 2

      • Anderlecht, Brussels Hoofdstedelijk Gewest

        Belgium

        Researchdreef 12

      • Pointe-Claire, QC

        Canada

        1 Avenue Holiday #647

      • 北京市

        China

        8 North Dongsanhuan Road, 北京市 China

      and 16 others

      Ypsomed Financials

      Summary financials

      Revenue (FY, 2022)
      CHF464.8M
      Gross profit (FY, 2022)
      CHF187.4M
      Net income (FY, 2022)
      CHF23.1M
      Cash (FY, 2022)
      CHF17.0M
      EBIT (FY, 2022)
      CHF28.6M
      Enterprise value
      $2.3B

      Footer menu